AMPK inhibits myoblast differentiation through a PGC-1α-dependent mechanism

David L. Williamson, David C. Butler, Stephen Alway

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Elevated phosphorylation of AMP-activated protein kinase (AMPK) has been shown to inhibit skeletal muscle growth in both culture and animal models, but its role in differentiation of muscle cells is less clear. p21 is known to have an important role in differentiation, but AMPK's role regulating p21 in differentiation in muscle cultures is unknown. Therefore, the purpose of this study was to determine the role of p21 in differentiation of skeletal muscle cells under conditions of elevated AMPK phosphorylation. Treating C 2C12 myoblast cultures with 1 mM 5-aminoimidazole-4- carboxamide 1-β-D-ribonucleoside (AICAR) for up to 24 h induced AMPK phosphorylation. Activation of AMPK reduced p21 protein and mRNA expression, which was associated with reduced G1/S cell cycle transition and p21 promoter activity. AICAR-treated myoblasts undergoing differentiation also had reduced p21 protein expression, reduced myotube formation, and myosin accumulation. When myotube cultures were treated with AICAR for 24 h, p21, myosin protein expression, and MyoD were significantly reduced. Myotube atrophy was also apparent compared with control conditions. Addition of compound C, an AMPK inhibitor, attenuated AICAR's negative effects on the myotube cultures. The nuclear expression of p21 protein appeared to be more affected by AICAR-treated myotubes than the cytosolic portion of p21 protein, which was attenuated with compound C treatment. Further analysis revealed that AICAR treatment increased PGC-1α and decreased FOXO3A protein expression, which was reversed with compound C cotreatment. Knockdown of PGC-1α with shRNA corroborated the compound C data, preserving nuclear FOXO3A and p21 protein expression. These data demonstrate that AICAR-induced AMPK phosphorylation inhibits cell cycle transition, reducing differentiation of myoblasts into myotubes, through PGC-1α-FOXO3A-p21.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume297
Issue number2
DOIs
StatePublished - Aug 1 2009
Externally publishedYes

Fingerprint

Aminoimidazole Carboxamide
AMP-Activated Protein Kinases
Ribonucleosides
Myoblasts
Skeletal Muscle Fibers
Phosphorylation
Proteins
Myosins
Muscle Cells
Cell Cycle
Skeletal Muscle
MyoD Protein
Protein Kinase Inhibitors
Small Interfering RNA
Atrophy
4-aminoimidazole
Animal Models
Muscles
Messenger RNA
Growth

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Physiology (medical)

Cite this

AMPK inhibits myoblast differentiation through a PGC-1α-dependent mechanism. / Williamson, David L.; Butler, David C.; Alway, Stephen.

In: American Journal of Physiology - Endocrinology and Metabolism, Vol. 297, No. 2, 01.08.2009.

Research output: Contribution to journalArticle

@article{ca42a6308d304fee94935c2bad6e96fe,
title = "AMPK inhibits myoblast differentiation through a PGC-1α-dependent mechanism",
abstract = "Elevated phosphorylation of AMP-activated protein kinase (AMPK) has been shown to inhibit skeletal muscle growth in both culture and animal models, but its role in differentiation of muscle cells is less clear. p21 is known to have an important role in differentiation, but AMPK's role regulating p21 in differentiation in muscle cultures is unknown. Therefore, the purpose of this study was to determine the role of p21 in differentiation of skeletal muscle cells under conditions of elevated AMPK phosphorylation. Treating C 2C12 myoblast cultures with 1 mM 5-aminoimidazole-4- carboxamide 1-β-D-ribonucleoside (AICAR) for up to 24 h induced AMPK phosphorylation. Activation of AMPK reduced p21 protein and mRNA expression, which was associated with reduced G1/S cell cycle transition and p21 promoter activity. AICAR-treated myoblasts undergoing differentiation also had reduced p21 protein expression, reduced myotube formation, and myosin accumulation. When myotube cultures were treated with AICAR for 24 h, p21, myosin protein expression, and MyoD were significantly reduced. Myotube atrophy was also apparent compared with control conditions. Addition of compound C, an AMPK inhibitor, attenuated AICAR's negative effects on the myotube cultures. The nuclear expression of p21 protein appeared to be more affected by AICAR-treated myotubes than the cytosolic portion of p21 protein, which was attenuated with compound C treatment. Further analysis revealed that AICAR treatment increased PGC-1α and decreased FOXO3A protein expression, which was reversed with compound C cotreatment. Knockdown of PGC-1α with shRNA corroborated the compound C data, preserving nuclear FOXO3A and p21 protein expression. These data demonstrate that AICAR-induced AMPK phosphorylation inhibits cell cycle transition, reducing differentiation of myoblasts into myotubes, through PGC-1α-FOXO3A-p21.",
author = "Williamson, {David L.} and Butler, {David C.} and Stephen Alway",
year = "2009",
month = "8",
day = "1",
doi = "10.1152/ajpendo.91007.2008",
language = "English (US)",
volume = "297",
journal = "American Journal of Physiology",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "2",

}

TY - JOUR

T1 - AMPK inhibits myoblast differentiation through a PGC-1α-dependent mechanism

AU - Williamson, David L.

AU - Butler, David C.

AU - Alway, Stephen

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Elevated phosphorylation of AMP-activated protein kinase (AMPK) has been shown to inhibit skeletal muscle growth in both culture and animal models, but its role in differentiation of muscle cells is less clear. p21 is known to have an important role in differentiation, but AMPK's role regulating p21 in differentiation in muscle cultures is unknown. Therefore, the purpose of this study was to determine the role of p21 in differentiation of skeletal muscle cells under conditions of elevated AMPK phosphorylation. Treating C 2C12 myoblast cultures with 1 mM 5-aminoimidazole-4- carboxamide 1-β-D-ribonucleoside (AICAR) for up to 24 h induced AMPK phosphorylation. Activation of AMPK reduced p21 protein and mRNA expression, which was associated with reduced G1/S cell cycle transition and p21 promoter activity. AICAR-treated myoblasts undergoing differentiation also had reduced p21 protein expression, reduced myotube formation, and myosin accumulation. When myotube cultures were treated with AICAR for 24 h, p21, myosin protein expression, and MyoD were significantly reduced. Myotube atrophy was also apparent compared with control conditions. Addition of compound C, an AMPK inhibitor, attenuated AICAR's negative effects on the myotube cultures. The nuclear expression of p21 protein appeared to be more affected by AICAR-treated myotubes than the cytosolic portion of p21 protein, which was attenuated with compound C treatment. Further analysis revealed that AICAR treatment increased PGC-1α and decreased FOXO3A protein expression, which was reversed with compound C cotreatment. Knockdown of PGC-1α with shRNA corroborated the compound C data, preserving nuclear FOXO3A and p21 protein expression. These data demonstrate that AICAR-induced AMPK phosphorylation inhibits cell cycle transition, reducing differentiation of myoblasts into myotubes, through PGC-1α-FOXO3A-p21.

AB - Elevated phosphorylation of AMP-activated protein kinase (AMPK) has been shown to inhibit skeletal muscle growth in both culture and animal models, but its role in differentiation of muscle cells is less clear. p21 is known to have an important role in differentiation, but AMPK's role regulating p21 in differentiation in muscle cultures is unknown. Therefore, the purpose of this study was to determine the role of p21 in differentiation of skeletal muscle cells under conditions of elevated AMPK phosphorylation. Treating C 2C12 myoblast cultures with 1 mM 5-aminoimidazole-4- carboxamide 1-β-D-ribonucleoside (AICAR) for up to 24 h induced AMPK phosphorylation. Activation of AMPK reduced p21 protein and mRNA expression, which was associated with reduced G1/S cell cycle transition and p21 promoter activity. AICAR-treated myoblasts undergoing differentiation also had reduced p21 protein expression, reduced myotube formation, and myosin accumulation. When myotube cultures were treated with AICAR for 24 h, p21, myosin protein expression, and MyoD were significantly reduced. Myotube atrophy was also apparent compared with control conditions. Addition of compound C, an AMPK inhibitor, attenuated AICAR's negative effects on the myotube cultures. The nuclear expression of p21 protein appeared to be more affected by AICAR-treated myotubes than the cytosolic portion of p21 protein, which was attenuated with compound C treatment. Further analysis revealed that AICAR treatment increased PGC-1α and decreased FOXO3A protein expression, which was reversed with compound C cotreatment. Knockdown of PGC-1α with shRNA corroborated the compound C data, preserving nuclear FOXO3A and p21 protein expression. These data demonstrate that AICAR-induced AMPK phosphorylation inhibits cell cycle transition, reducing differentiation of myoblasts into myotubes, through PGC-1α-FOXO3A-p21.

UR - http://www.scopus.com/inward/record.url?scp=68049100075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68049100075&partnerID=8YFLogxK

U2 - 10.1152/ajpendo.91007.2008

DO - 10.1152/ajpendo.91007.2008

M3 - Article

VL - 297

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0193-1849

IS - 2

ER -